What is CorWave?
CorWave is a French company headquartered in Clichy, focused on the development of innovative cardiac assist devices. The company operates within the highly specialized and regulated field of medical technology, aiming to provide advanced solutions for cardiovascular conditions. Its work involves intricate engineering and clinical validation to bring life-saving or life-enhancing devices to market, addressing a significant unmet need in cardiac care.
How much funding has CorWave raised?
CorWave has raised a total of $86.7M across 3 funding rounds:
Series A
$4M
Series B
$17.1M
Series C
$65.6M
Series A (2013): $4M with participation from G�rard Hasco�t
Series B (2016): $17.1M led by Bpifrance, Ysios Capital, Sofinnova Partners, Novo Seeds, and Seventure Partners
Series C (2023): $65.6M supported by Bpifrance, Seventure Partners, EIC Fund, Novo Holdings, Sofinnova Partners, and Ysios Capital
Key Investors in CorWave
Bpifrance
Bpifrance is a French public investment bank that finances companies at all stages of development, supporting innovation and international expansion. They provide credit, guarantees, and equity, along with acceleration programs for businesses.
Novo Holdings
Novo Holdings is a Danish investment company wholly owned by the Novo Nordisk Foundation, focusing on life sciences and healthcare investments.
Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specializing in life sciences, investing from seed to later stages in healthcare and sustainability innovations.
What's next for CorWave?
The substantial enterprise-level funding CorWave has attracted, particularly the recent strategic investment, positions the company for significant expansion. This capital infusion is expected to fuel further research and development, scale manufacturing capabilities, and support broader commercialization efforts. The company's focus on cardiac assist devices suggests a strategic push to capture a larger share of the cardiovascular medical device market, potentially through strategic partnerships, expanded clinical trials, and global market entry. The ongoing backing from prominent investors indicates strong confidence in CorWave's technology and its potential to disrupt the cardiac care landscape.
See full CorWave company page
